Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2010 Mar;35(3):148-57.

Impact of Rituximab (Rituxan) on the Treatment of B-Cell Non-Hodgkin's Lymphoma

Efrat Dotan, Charu Aggarwal, Mitchell R Smith

Impact of Rituximab (Rituxan) on the Treatment of B-Cell Non-Hodgkin's Lymphoma

Efrat Dotan et al. P T. 2010 Mar.

Abstract

Non-Hodgkin's lymphoma (NHL) is the most common hematological malignancy in adults, with B-cell lymphomas accounting for 85% of all NHLs. The most substantial advancement in the treatment of B-cell malignancies, since the advent of combination chemotherapy, has been the addition of the monoclonal anti-CD20 antibody rituximab (Rituxan). Since its initially reported single-agent activity in indolent lymphomas in 1997, the role of rituximab has expanded to cover both indolent and aggressive lymphomas.This article focuses on the impact of rituximab on the treatment, survival, and long-term outcomes of patients with indolent and aggressive lymphomas over the past two decades.

Keywords: non-Hodgkin’s lymphoma; rituximab.

PubMed Disclaimer

Figures

Figure 1
Figure 1
Overall survival according to treatment regimen in diffuse large B-cell lymphoma. Results of a randomized trial of non-rituximab containing regimens as historical controls for British Columbia outcome data with R-CHOP. MACOP-B = methotrexate, Adriamycin, cyclophosphamide (Cytoxan), Oncovin, prednisone–bleomycin; m-BACOD = methotrexate–bleomycin, Adriamycin, cyclophosphamide, Oncovin, dexamethasone; ProMACE–Cyta BOM = prednisone, methotexate, Adriamycin, cyclophosphamide, etoposide/cytarabine, bleomycin, Oncovin, methotrexate; R-CHOP = rituximab–cyclophosphamide, hydroxydaunorubicin (doxorubicin), Oncovin (vincristine), prednisone. (From Sehn LH, et al. J Clin Oncol 2005;23:5027–5033. © 2008 American Society of Clinical Oncology; and Fisher RI, et al. N Engl J Med 1993;328:1002–1006. © 1993 Massachusetts Medical Society.43)
See this image and copyright information in PMC

References

    1. Jemal A, Siegel R, Ward E. Cancer statistics, 2008. CA Cancer J Clin. 2008;58(2):71–96. - PubMed
    1. Rudiger T, Muller-Hermelink HK. WHO classification of malignant lymphomas. Radiologe. 2002;42(12):936–942. - PubMed
    1. Harris NL, Jaffe ES, Diebold J, et al. The World Health Organization Classification of Neoplastic Diseases of the Hematopoietic and Lymphoid Tissues. Report of the Clinical Advisory Committee meeting. Airlie House, Virginia, November 1997; Ann Oncol; 1999. pp. 1419–1432. - PubMed
    1. Armitage JO, Weisenburger DD. New approach to classifying non-Hodgkin’s lymphomas: Clinical features of the major histologic subtypes. Non-Hodgkin’s Lymphoma Classification Project. J Clin Oncol. 1998;16(8):2780–2795. - PubMed
    1. Tedder TF, Engel P. CD20: A regulator of cell–cycle progression of B lymphocytes. Immunol Today. 1994;15(9):450–454. - PubMed